PMID: 25734964Mar 4, 2015Paper

Managing advanced prostate cancer: the rapidly changing treatment landscape

The American Journal of Managed Care
Robert Dreicer

Abstract

The FDA approval of 5 new therapeutic agents within a 4-year time frame, all of which potentially improve survival for patients with metastatic castration-resistant prostate cancer, is unprecedented in oncology. The diversity of the mechanisms of action of these agents is compelling, including the first and only therapeutic cancer vaccine, the first approved use of an alpha emitter, 2 novel next generation hormonal therapy agents, and a second-generation taxane. However, with this therapeutic bounty comes new challenges in the optimal use of these new and expensive agents in a disease well known for its heterogeneity.

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
C N Sternberg
Current Opinion in Supportive and Palliative Care
Raya Leibowitz-Amit, Anthony M Joshua
Asian Journal of Andrology
Kouji Izumi, Mikio Namiki
© 2022 Meta ULC. All rights reserved